Why Do Gay Men Get HIV More Often Than Others?

Gay men face higher HIV rates due to biological, social, and systemic factors — here’s what the science actually says and what prevention looks like today.

The short answer is biology plus math. Receptive anal sex carries a per-act HIV transmission risk roughly ten to twenty times higher than vaginal sex, and when a sexually transmitted virus is already more common within a sexual network, each encounter is more likely to involve an infected partner. Those two facts alone account for the bulk of the disparity. But the full picture involves layers of reinforcing factors: the cellular makeup of rectal tissue, high rates of other sexually transmitted infections that make HIV transmission easier, gaps in diagnosis that keep viral loads high, and social stigma that discourages testing and prevention. None of these factors operates alone, and none of them is inherent to being gay. They interact in ways that make the epidemic stubbornly persistent even as powerful prevention tools become available.

Rectal Tissue Is Biologically Vulnerable to HIV

HIV needs specific immune cells to infect, particularly CD4+ T cells that carry a surface protein called CCR5. The rectum is dense with these cells. Research comparing tissue from different parts of the gut found that more than three times as many macrophages in the rectum expressed CCR5 compared with the colon, making rectal macrophages look biologically closer to the HIV-susceptible cells found in vaginal tissue than to the relatively resistant cells found higher in the digestive tract. In other words, the last stretch of the intestinal tract is, from HIV’s perspective, an unusually welcoming environment.

The rectal lining is also just one cell layer thick in places, far more fragile than the multi-layered epithelium of the vagina. Micro-tears during sex can expose those underlying target cells directly to the virus. And research on young men who have sex with men has found that their rectal immune environment shows increased CD4+ T cell proliferation and a microbiome enriched with bacteria previously linked to HIV acquisition risk. When rectal tissue from these men was challenged with HIV in the lab, it supported higher viral replication. Separate work has shown that the gut microbiome composition in men who have sex with men is associated with elevated frequencies of HIV co-receptor CCR5 on CD4+ T cells in colon biopsies, suggesting the microbiome itself may influence susceptibility.

The Numbers Tell a Stark Story

A systematic review pooling data from multiple studies estimated the per-act risk of HIV transmission during receptive anal intercourse at about 138 per 10,000 exposures. Compare that to receptive vaginal intercourse at about 8 per 10,000, or insertive vaginal intercourse at about 4 per 10,000. Insertive anal intercourse fell in between, at roughly 11 per 10,000. That means a single act of receptive anal sex is roughly seventeen times riskier than a single act of receptive vaginal sex, and roughly thirty-five times riskier than insertive vaginal sex.

A separate meta-analysis focused specifically on anal intercourse arrived at a similar estimate for per-act receptive risk, around 1.4%, and found no significant difference in per-act risk between heterosexual and same-sex anal intercourse. That point matters: the biology of the rectum doesn’t care about the gender or sexual orientation of the person. What makes this relevant to gay men specifically is that anal sex is a common part of their sexual lives in a way it isn’t for most heterosexual couples, so the elevated per-act risk applies to a much larger share of their sexual encounters.

Within anal sex, the details also matter. A study of gay men in Sydney estimated that receptive anal intercourse with ejaculation carried a per-contact probability of about 1.43%, roughly twice that of withdrawal before ejaculation. For the insertive partner, circumcision status made a difference: the estimated per-contact probability was about 0.11% for circumcised men and 0.62% for uncircumcised men. Semen itself may play a role: laboratory research has identified naturally occurring protein fragments in seminal fluid that form structures called SEVI, which capture HIV particles and boost their ability to attach to target cells by several orders of magnitude.

Other STIs Act as Amplifiers

Sexually transmitted infections other than HIV don’t just coexist with it — they actively boost its transmission. Both ulcerative STIs like syphilis and herpes and non-ulcerative ones like gonorrhea and chlamydia increase both the infectiousness of someone who has HIV and the susceptibility of someone who doesn’t. The mechanism is straightforward: STIs cause inflammation, and inflammation floods tissue with exactly the immune cells HIV wants to infect.

Syphilis and herpes simplex virus type 2 are particularly potent partners for HIV. Tissue affected by either infection has been shown to contain increased numbers of CCR5-bearing T cells, the same cells HIV targets for entry. Even asymptomatic rectal infections with chlamydia or gonorrhea — infections that cause no symptoms and may go undetected for months — have been linked to increased systemic immune activation, potentially raising HIV acquisition risk.

Gay and bisexual men have higher rates of these STIs than the general population, partly because many of the same biological and network factors that drive HIV transmission also drive other infections. The result is a feedback loop: STIs make HIV easier to catch, HIV weakens the immune system and makes STIs harder to clear, and the ongoing inflammation makes further HIV transmission more likely.

Network Prevalence Changes the Math

Even a high per-act transmission risk matters only if the other person actually has HIV. This is where sexual network dynamics come in. Because HIV has been circulating among men who have sex with men for over four decades, background prevalence within gay male communities is substantially higher than in the general population. In sub-Saharan Africa, where both general and MSM-specific HIV prevalence are high, a systematic review and meta-analysis found that HIV prevalence was about five times higher among men who have sex with men compared to men in the general population. In Western and Central Africa specifically, the prevalence ratio was even wider, around 11 to 1.

High background prevalence means any given unprotected sexual encounter is more likely to involve a partner who has HIV, whether either person knows it or not. This creates a self-reinforcing cycle: the more people in a network are infected, the more new infections occur, which raises prevalence further. Heterosexual populations can have similarly devastating epidemics when prevalence gets high enough, as seen in southern Africa, but in most of the world, the concentrated prevalence among MSM means that a gay man’s sexual network exposes him to more risk per encounter than a heterosexual man’s network, independent of the type of sex involved.

Undiagnosed Infection Drives Transmission

A person who doesn’t know they have HIV can’t take treatment to suppress the virus, and a person with unsuppressed virus is far more infectious. The first weeks of HIV infection, the acute phase, are especially dangerous: viral load can spike to extremely high levels, and the person usually has no symptoms. A meta-analysis estimated that during a two-month primary infection, the rate of transmission was roughly 37 times higher than what chronic-stage viral load values alone would predict.

CDC modeling of the U.S. HIV care continuum in 2016 found that people who were acutely infected and unaware had a transmission rate of about 16 per 100 person-years, the highest of any group. Those unaware but past the acute phase transmitted at about 8 per 100 person-years. Together, people who hadn’t been diagnosed accounted for a significant share of all new transmissions, while those on treatment with suppressed virus accounted for zero. An earlier analysis estimated that roughly 30% of transmissions per year were attributable to undiagnosed individuals, while those diagnosed but not retained in care contributed the majority of the remainder.

This means anything that delays testing or keeps people out of care drives transmission. And for gay men, several forces conspire to do exactly that.

Stigma Keeps People Away from Testing and Treatment

Homophobia isn’t just a social problem — it’s an epidemiological one. Research among Chinese men who have sex with men found that experienced homophobia reduced the likelihood of recent HIV testing, with about a third of that effect operating through depression. Qualitative studies in multiple countries echo this finding: men describe avoiding clinics because they fear being judged or outed, or because past experiences of stigma have made them distrust healthcare providers.

At a structural level, the damage is measurable. A study of gay and bisexual men in Australia found that those living in regions with higher structural stigma were less likely to undergo HIV or STI testing, less likely to be aware of or using biomedical prevention, and — among those living with HIV — less likely to be on treatment and attending clinical visits. That connects directly to the transmission dynamics described above: less testing means more undiagnosed infection, less treatment means higher viral loads, and higher viral loads mean more transmission.

For Black and Latino gay and bisexual men, the picture is worse. Intersecting layers of racism and homophobia compound to create deeper distrust of medical systems. Research has documented how young Black men who have sex with men perceive healthcare settings as hostile, reducing engagement with prevention tools like PrEP. In Nigeria, where same-sex behavior is criminalized, gay and bisexual men described experiencing rejection by family, harassment, and violence from both the public and police, leading to mental health problems and social isolation that fed into riskier sexual behavior. Internalized stigma has its own effects: among HIV-positive gay and bisexual men, internalized homophobia and HIV stigma were linked through emotional distress to symptoms of sexual compulsivity, which in turn can increase transmission risk.

Chemsex and Risk Behavior

Sexualized drug use, commonly called chemsex, is a well-documented contributor to HIV risk among men who have sex with men. A study of HIV-positive men in the UK found that those who engaged in chemsex had roughly six times the odds of having condomless anal sex and more than six times the odds of being diagnosed with a bacterial STI. Injection of drugs during sex (“slamsex”) was associated with even steeper odds of hepatitis C. Research from Thailand found a similar pattern: men classified as exclusive chemsex users were more likely to be HIV-positive, to report six or more sexual partners, and to skip condoms during anal sex.

Chemsex doesn’t exist in a vacuum. The same stigma and minority stress dynamics discussed above help explain why some men turn to substances during sex. When your social environment makes your sexuality a source of shame or anxiety, substances that lower inhibitions and heighten pleasure can feel like a solution, even though they raise the risk of exactly the infections that stigma has already made harder to prevent.

Serosorting and Its Limits

One strategy some gay men use to manage risk is serosorting — choosing sexual partners believed to share the same HIV status. The logic seems sound: if both partners are negative, there’s no virus to transmit. But in practice, serosorting is only as reliable as the information it’s based on. A study of self-identified HIV-negative men who have sex with men found that about a third engaged in serosorting, and these men had more condomless anal sex partners, apparently believing the strategy protected them.

A meta-analysis confirmed the complicated math: compared to consistent condom use, serosorting was associated with increased HIV risk. But compared to condomless sex with partners of unknown or different HIV status, it roughly halved the risk. The strategy works as harm reduction for men who aren’t going to use condoms consistently, but it fails when partners don’t actually know their status or are in the highly infectious acute phase when standard tests can still come back negative. That window of acute infection, when someone may have contracted HIV just weeks ago and tests haven’t caught up yet, is the blind spot serosorting cannot cover.

Prevention Tools That Are Changing the Equation

The most powerful finding in HIV prevention in recent years is Undetectable = Untransmittable, or U=U. The PARTNER2 study followed 782 serodifferent gay couples — one partner HIV-positive and on treatment, the other negative — for nearly 1,600 couple-years of follow-up, during which they reported over 76,000 instances of condomless anal sex. The number of within-couple HIV transmissions linked by genetic analysis: zero. When someone with HIV takes treatment and achieves an undetectable viral load, the risk of sexual transmission is effectively zero. That result holds for anal sex, not just vaginal sex, which is why it matters so much for gay men.

Pre-exposure prophylaxis (PrEP), in which HIV-negative people take medication to prevent infection, has also reshaped the landscape. Modeling suggests that long-acting injectable PrEP, given every two months, could reduce new HIV infections among men who have sex with men by about 44% compared to no PrEP — outperforming daily oral PrEP’s modeled reduction of about 33% — largely because injections eliminate the problem of forgetting pills. But access remains uneven. The same stigma that discourages HIV testing also discourages PrEP uptake, and the racial disparities in PrEP use are striking — young Black men who have sex with men are significantly less likely to use PrEP than their white counterparts.

Doxycycline as Post-Exposure STI Prevention

Because other STIs amplify HIV risk so dramatically, there’s growing interest in using the antibiotic doxycycline as a post-exposure prophylaxis for bacterial STIs like syphilis, chlamydia, and gonorrhea. The concept, known as doxy-PEP, involves taking a dose of doxycycline within 72 hours of condomless sex. Clinical trials have shown significant reductions in bacterial STI rates, and gay and bisexual men in qualitative studies have expressed interest in the approach, citing its simplicity and the anxiety reduction it offers. Concerns include the potential for antibiotic resistance and stigma around its use. If doxy-PEP reduces STI rates substantially, it could indirectly reduce HIV transmission by removing one of the biological amplifiers that keep incidence high.

The picture that emerges from all of this is not one of personal failing or inherent vulnerability. It is a collision of biology, network dynamics, diagnostic gaps, social marginalization, and unequal access to prevention tools. Each factor on its own would modestly increase risk. Layered together, they produce the dramatic disparity in HIV rates that has defined the epidemic since the 1980s. The tools to close that gap exist. The barriers to deploying them are, at this point, largely social and structural rather than scientific.